Monitoring treatment response in breast cancer is of great importance and FDG PET has demonstrated its utility in this indication. FDG PET must be performed in patients with advanced disease treated ...

Reston, Va.—Seven medical imaging groups wrote a joint letter to the Centers for Medicare and Medicaid Services (CMS) to formally request coverage of two fluorodeoxyglucose (FDG) positron emission ...

Pretreatment 18 F-FDG PET/CT scans from three study populations (N = 100, N = 39, N = 70) were used, comprising two single-institutional protocols and one publicly available data set. A clinician (V.J ...

Staging locally advanced breast cancer patients with 18 F-labeled fluorodeoxyglucose (FDG) PET-CT detected more distant metastases -- and thus reduced the number of patients who received combined ...

A novel quantitative PET- and MRI-based imaging approach can objectively identify a recently recognized type of ...

Miami Beach, Fla. — The prognosis for patients with stage II and III inoperable non-small cell lung cancer (NSCLC) is poor, with only about 15 percent of patients surviving at five years ...

Efficacy and safety of camrelizumab combined with chemotherapy (irinotecan combined with platinum) followed by camrelizumab combined with apatinib in the first-line treatment of advanced small cell ...

Positron emission tomography (PET) provided objective evidence of response to treatment with tocilizumab (Actemra) in giant cell arteritis, according to a study by researchers from the National ...

Positron emission tomography (PET) scans can detect cancer earlier than other imaging tests. But some types of cancer are harder to detect on a PET scan. In particular, they may miss cancers that ...